AURA
Aura Biosciences, Inc.
There isn't enough reported data to score AURA yet.
AURA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
AURA's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
AURA PE Valuation
AURA has no meaningful PE right now: it lost money over the past year.
AURA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect AURA's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
AURA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.61 | +$0.33 |
| Q2 2026 | -$1.72 | +$0.24 |
| Q1 2026 | -$1.71 | +$0.19 |
| Q4 2025 | -$1.76 | -$0.01 |
| Q3 2025 | -$1.94 | -$0.20 |
| Q2 2025 | -$1.96 | -$0.16 |
| Q1 2025 | -$1.90 | -$0.03 |
| Q4 2024 | -$1.75 | +$0.18 |
AURA is still losing money, but less than at its worst: $1.61 per share over the past year, against $2.00 at its worst in mid-2023.
AURA Quarterly Revenue
AURA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.5M | -$6.3M |
| Q2 2026 | -$32.5M | -$11.7M |
| Q1 2026 | -$30M | -$6.5M |
| Q4 2025 | -$20.6M | +$3.6M |
| Q3 2025 | -$20.2M | -$4.6M |
| Q2 2025 | -$20.8M | -$4.2M |
| Q1 2025 | -$23.5M | +$998K |
| Q4 2024 | -$24.3M | -$6.5M |
AURA has burned cash in almost every quarter: −$110M over the past year, against −$89M the year before.
AURA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +17% | +16.2M shares |
| 1 year | +68% | +45.1M shares |
| 3 years | +191% | +72.9M shares |
| 5 years | +468% | +91.5M shares |
AURA has 111M diluted shares, up 68% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AURA Net Leverage
AURA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AURA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.8 | Neutral |
| Stochastic | 28.2 | Neutral |
AURA's weekly RSI is 54 (neutral) and its Stochastic is 28 (neutral).
AURA PE vs Healthcare Sector
AURA has no meaningful PE right now: it lost money over the past year.
AURA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.35 | 12% above |
| 20 week MA | $6.92 | 2.7% above |
| 50 week MA | $6.58 | 8.1% above |
| 100 week MA | $6.58 | 8.1% above |
| 200 week MA | $7.91 | 10% below |
AURA has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 10% below its 200-week average.
AURA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $14.8 | $16.0 | +8.4% |
| 2022 | $16.0 | $10.9 | -32% |
| 2023 | $10.9 | $8.86 | -19% |
| 2024 | $8.86 | $8.33 | -6% |
| 2025 | $8.33 | $5.87 | -30% |
| 2026 YTD | $5.87 | $7.11 | +21% |
AURA has finished four years in a row lower, and it's up 21% so far in 2026.